BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
854 results:

  • 1. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
    Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
    Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
    Marius W; Leticia OF; Friedrich KN; Stephan M; Louisa H; Tabea S; Elisa S; Pauline W; Yi D; Qi M; Barbara S; Carsten B; Walter F; Jasmin W; Franziska B
    Oncoimmunology; 2024; 13(1):2346359. PubMed ID: 38737794
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. An oncolytic HSV-1 armed with Visfatin enhances antitumor effects by remodeling tumor microenvironment against murine pancreatic cancer.
    Zhao J; Wang H; Chen J; Wang C; Gong N; Zhou F; Li X; Cao Y; Zhang H; Wang W; Zheng H; Zhang C
    Biochem Biophys Res Commun; 2024 Jul; 718():149931. PubMed ID: 38723415
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets.
    Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
    JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Apolipoprotein E is a prognostic factor for pancreatic cancer and associates with immune infiltration.
    Wu B; Yang X; Chen F; Song Z; Ding X; Wang X
    Cytokine; 2024 Jul; 179():156628. PubMed ID: 38704962
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Efficacy and safety of pd-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
    Chen Y; Liu X; Hu Y; Xia L
    Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
    Friedman CF; Manning-Geist BL; Zhou Q; Soumerai T; Holland A; Da Cruz Paula A; Green H; Ozsoy MA; Iasonos A; Hollmann T; Leitao MM; Mueller JJ; Makker V; Tew WP; O'Cearbhaill RE; Liu YL; Rubinstein MM; Troso-Sandoval T; Lichtman SM; Schram A; Kyi C; Grisham RN; Causa Andrieu P; Wherry EJ; Aghajanian C; Weigelt B; Hensley ML; Zamarin D
    Nat Med; 2024 May; 30(5):1330-1338. PubMed ID: 38653864
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
    Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
    Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
    Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
    World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.
    Nie H; Saini P; Miyamoto T; Liao L; Zielinski RJ; Liu H; Zhou W; Wang C; Murphy B; Towers M; Yang T; Qi Y; Kannan T; Kossenkov A; Tateno H; Claiborne DT; Zhang N; Abdel-Mohsen M; Zhang R
    Nat Commun; 2024 Apr; 15(1):2853. PubMed ID: 38565883
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Circulating tumor-associated antigen-specific IFNγ
    Murakami H; Takahama S; Akita H; Kobayashi S; Masuta Y; Nagatsuka Y; Higashiguchi M; Tomokuni A; Yoshida K; Takahashi H; Doki Y; Eguchi H; Matsuura N; Yamamoto T
    Front Immunol; 2024; 15():1363568. PubMed ID: 38550601
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
    Kasikova L; Rakova J; Hensler M; Lanickova T; Tomankova J; Pasulka J; Drozenova J; Mojzisova K; Fialova A; Vosahlikova S; Laco J; Ryska A; Dundr P; Kocian R; Brtnicky T; Skapa P; Capkova L; Kovar M; Prochazka J; Praznovec I; Koblizek V; Taskova A; Tanaka H; Lischke R; Mendez FC; Vachtenheim J; Heinzelmann-Schwarz V; Jacob F; McNeish IA; Halaska MJ; Rob L; Cibula D; Orsulic S; Galluzzi L; Spisek R; Fucikova J
    Nat Commun; 2024 Mar; 15(1):2528. PubMed ID: 38514660
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian cancer.
    Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
    Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
    [No Abstract]    [Full Text] [Related]  

  • 15. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
    Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
    Enzler T; Shi J; McGue J; Griffith BD; Sun L; Sahai V; Nathan H; Frankel TL
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474199
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.
    Nakazawa Y; Miyano M; Tsukamoto S; Kogai H; Yamamoto A; Iso K; Inoue S; Yamane Y; Yabe Y; Umihara H; Taguchi J; Akagi T; Yamaguchi A; Koga M; Toshimitsu K; Hirayama T; Mukai Y; Machinaga A
    Nat Commun; 2024 Mar; 15(1):2192. PubMed ID: 38467634
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Machine learning developed a CD8
    Chen R; Zheng Y; Fei C; Ye J; Fei H
    Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
    Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
    Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. 4-Hydroxyphenylpyruvate Dioxygenase-Like predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.
    Li H; Liu J; Wang S; Xu Y; Tang Q; Ying G
    Aging (Albany NY); 2024 Mar; 16(5):4327-4347. PubMed ID: 38451188
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 43.